NasdaqGM:CATB

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. More Details


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Catabasis Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CATB is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.

Volatility Over Time: CATB's weekly volatility has increased from 14% to 23% over the past year.


Market Performance


7 Day Return

20.8%

CATB

2.8%

US Biotechs

1.5%

US Market


1 Year Return

-66.8%

CATB

27.3%

US Biotechs

22.3%

US Market

Return vs Industry: CATB underperformed the US Biotechs industry which returned 27.2% over the past year.

Return vs Market: CATB underperformed the US Market which returned 22.1% over the past year.


Shareholder returns

CATBIndustryMarket
7 Day20.8%2.8%1.5%
30 Day44.4%7.8%8.8%
90 Day-67.8%17.5%10.8%
1 Year-66.8%-66.8%29.5%27.3%25.1%22.3%
3 Year-89.3%-89.3%26.5%20.1%49.5%39.6%
5 Year-97.7%-97.7%21.0%12.7%105.8%83.3%

Long-Term Price Volatility Vs. Market

How volatile is Catabasis Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Catabasis Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

0.78x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CATB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CATB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CATB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CATB is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CATB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CATB is good value based on its PB Ratio (0.8x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Catabasis Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

31.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CATB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CATB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CATB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if CATB's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if CATB's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CATB's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Catabasis Pharmaceuticals performed over the past 5 years?

4.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CATB is currently unprofitable.

Growing Profit Margin: CATB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CATB is unprofitable, but has reduced losses over the past 5 years at a rate of 4.9% per year.

Accelerating Growth: Unable to compare CATB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CATB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.8%).


Return on Equity

High ROE: CATB has a negative Return on Equity (-70.84%), as it is currently unprofitable.


Next Steps

Financial Health

How is Catabasis Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: CATB's short term assets ($55.5M) exceed its short term liabilities ($7.0M).

Long Term Liabilities: CATB's short term assets ($55.5M) exceed its long term liabilities ($559.0K).


Debt to Equity History and Analysis

Debt Level: CATB is debt free.

Reducing Debt: CATB has no debt compared to 5 years ago when its debt to equity ratio was 16.4%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CATB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CATB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Catabasis Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CATB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CATB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CATB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CATB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CATB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Jill Milne (52 yo)

12.5yrs

Tenure

US$1,032,797

Compensation

Ms. Jill C. Milne, PhD is a Co-founder of Catabasis Pharmaceuticals, Inc., has been its President and Chief Executive Officer since June 2008. She served as Principal Financial Officer at Catabasis Pharmac...


CEO Compensation Analysis

Compensation vs Market: Jill's total compensation ($USD1.03M) is above average for companies of similar size in the US market ($USD560.00K).

Compensation vs Earnings: Jill's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Jill Milne
Co-Founder12.5yrsUS$1.03m0.13%
$ 50.4k
Andrew Nichols
Chief Scientific Officer4.17yrsUS$631.95k0%
$ 0
Joanne Donovan
Chief Medical Officer & Senior VP of Clinical Development9.42yrsUS$713.71k0.00020%
$ 77.1
Noah Clauser
Chief Financial Officer1yrno datano data
Benjamin Harshbarger
Senior VP & General Counsel0.50yrno datano data
Joseph Johnston
Senior Vice President of Regulatory Affairs0.25yrno datano data
Andrew Komjathy
Chief Commercial Officer1.25yrsno datano data
Andrea Matthews
Vice President of Corporate Affairs3.25yrsno datano data

2.3yrs

Average Tenure

54.5yo

Average Age

Experienced Management: CATB's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jill Milne
Co-Founder12.5yrsUS$1.03m0.13%
$ 50.4k
Michael Kishbauch
Independent Director4.67yrsUS$82.40k0%
$ 0
Edward Scolnick
Member of Scientific Advisory Boardno datano datano data
Kenneth Bate
Independent Chairman of the Board4.83yrsUS$113.34k0%
$ 0
Arthur Rubenstein
Member of Scientific Advisory Boardno datano datano data
Gregory Lapointe
Independent Director1.92yrsUS$81.57k0%
$ 0
Johannes Jacob Kastelein
Member of Scientific Advisory Boardno datano datano data
Michael Jirousek
Member of Scientific Advisory Board5.17yrsUS$589.63kno data
Jay Horton
Member of Scientific Advisory Boardno datano datano data
Roger Ulrich
Member of Scientific Advisory Boardno datano datano data
Eric Brass
Member of Scientific Advisory Boardno datano datano data
Sekar Kathiresan
Member of Scientific Advisory Boardno datano datano data

4.8yrs

Average Tenure

68yo

Average Age

Experienced Board: CATB's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 70.2%.


Top Shareholders

Company Information

Catabasis Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Catabasis Pharmaceuticals, Inc.
  • Ticker: CATB
  • Exchange: NasdaqGM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$38.562m
  • Shares outstanding: 20.08m
  • Website: https://www.catabasis.com

Number of Employees


Location

  • Catabasis Pharmaceuticals, Inc.
  • 100 High Street
  • 28th Floor
  • Boston
  • Massachusetts
  • 2110
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CATBNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDJun 2015
209ADB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2015

Biography

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/04 23:42
End of Day Share Price2020/12/04 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.